Company intelligence / Profile preview
Ottimo Pharma
London, United Kingdomottimopharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody designed as a dual pathway, biparatopic single-agent IgG therapy targeting both immune checkpoint inhibition and angiogenesis in cancer treatment. Currently in IND-enabling studies.
- Therapeutic areas
- Oncology
- Modalities
- Bifunctional antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Ottimo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ottimo Pharma.